Answers are grounded in this paper and cite their sources.
Echinococcosis is a zoonotic parasitic disease caused by infection with the larval stage of the Echinococcus tapeworm, it primarily affects the liver and is a significant public health issue in the agricultural and pastoral regions of western China.At present, the primary treatment regimen for active-phase echinococcosis is radical resection of the lesion combined with albendazole therapy. however, this approach has limitations, including postoperative recurrence, drug toxicity, and insufficient bioavailability. The gut microbiota participates in the immune regulation of the liver via the gut-liver axis; probiotics can reshape the gut microbiome and modulate the host immune response, offering new insights for the adjunctive treatment of echinococcosis. Currently, research in this field is largely limited to animal models, and there is a lack of evidence from human clinical trials. This paper reviews the progress of animal studies on probiotic interventions for echinococcosis, examines the pathological role of the gut microbiota–gut–liver axis in echinococcosis, and summarizes the potential mechanisms of action of probiotics, their use as vaccine carriers, and their synergistic effects with anti-echinococcal drugs. It also analyzes the current bottlenecks and shortcomings in this research, providing a theoretical framework for future basic, translational, and clinical investigations.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: